Biora Therapeutics, Inc.
BIOR · OTC
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $1 | $74 |
| % Growth | -98.7% | -75.5% | -98.3% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $93 |
| Gross Profit | $0 | $0 | $1 | -$19 |
| % Margin | 100% | 100% | 100% | -25.7% |
| R&D Expenses | $30 | $24 | $46 | $48 |
| G&A Expenses | $0 | $0 | $69 | $75 |
| SG&A Expenses | $37 | $38 | $73 | $128 |
| Sales & Mktg Exp. | $0 | $0 | $5 | $6 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $67 | $62 | $119 | $176 |
| Operating Income | -$67 | -$62 | -$118 | -$108 |
| % Margin | -1,678,575% | -20,256.1% | -9,449.6% | -144.8% |
| Other Income/Exp. Net | -$57 | $13 | -$61 | -$35 |
| Pre-Tax Income | -$124 | -$49 | -$179 | -$143 |
| Tax Expense | -$0 | -$0 | -$0 | -$38 |
| Net Income | -$124 | -$38 | -$179 | -$193 |
| % Margin | -3,102,875% | -12,510.5% | -14,316% | -259.1% |
| EPS | -78.7 | -6.4 | -46.42 | -86.3 |
| % Growth | -1,129.7% | 86.2% | 46.2% | – |
| EPS Diluted | -78.7 | -6.4 | -46.42 | -86.3 |
| Weighted Avg Shares Out | 2 | 8 | 4 | 2 |
| Weighted Avg Shares Out Dil | 2 | 8 | 4 | 2 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $10 | $11 | $13 | $10 |
| Depreciation & Amortization | $1 | $1 | $1 | $1 |
| EBITDA | -$114 | -$37 | -$165 | -$106 |
| % Margin | -2,851,350% | -12,246.9% | -13,197% | -142.9% |